PAI-1 Inhibitor TM5614 Targets Aging, Senescence, and Cancer in One Molecule

PAI-1 (encoded by SERPINE1) is the principal physiological inhibitor of tissue-type and urokinase plasminogen activators, and its classical role is hemostatic control of fibrinolysis. This review from Tohoku University's Department of Molecular Medicine and Therapy reframes PAI-1 as a pleiotropic 'immune-aging checkpoint' — a molecular node through which senescent, stromal, malignant, and inflammatory cells collectively enforce immune evasion, tissue dysfunction, and organismal aging. The central thesis is that PAI-1 is not merely a downstream biomarker but an active effector of the senescence-associated secretory phenotype (SASP), chronic low-grade inflammation (inflammaging), extracellular matrix fibrosis, and a prothrombotic vascular state that compounds with age.

At the molecular level, PAI-1 adopts a conformationally dynamic SERPIN fold whose active form is stabilized by vitronectin in the extracellular matrix. SERPINE1 transcription is upregulated by TGF-beta, TNF-alpha, angiotensin II, oxidative stress, hypoxia, and senescence pathways. Intracellularly, PAI-1 reinforces p53/p21 signaling in alveolar epithelial and other cell types by inhibiting proteasome-mediated p53 degradation, thereby locking cells into cycle arrest and sustaining the senescent phenotype — a feedback loop that worsens with biological age. Senescent cells further upregulate PD-L1 immune checkpoint molecules, creating local immune escape zones analogous to tumor microenvironments, and PAI-1-rich niches amplify this effect by promoting macrophage recruitment, fibroblast activation, and impaired efferocytosis.

The most compelling human genetic evidence comes from Old Order Amish carriers of a rare SERPINE1 loss-of-function mutation. These individuals display significantly reduced PAI-1 activity, favorable metabolic parameters, and longer lifespan relative to non-carriers — a natural experiment suggesting that partial, lifelong reduction of PAI-1 translates into improved human healthspan. In klotho-deficient accelerated-aging mice, PAI-1 deficiency or pharmacological suppression delayed senescence-associated pathology, preserved organ structure and function, and prolonged survival, reinforcing the genetic human data with a manipulable animal model.

Preclinical studies across multiple TM-series compounds demonstrate anti-thrombotic, anti-fibrotic, anti-senescent, and tumor-microenvironment-modulating effects. TM5275 and TM5441 reduced renal fibrosis and inflammatory markers in diabetic nephropathy models without obvious bleeding complications. TM5275 attenuated liver fibrosis by suppressing hepatic stellate cell activation and collagen synthesis in a metabolic-syndrome model, and ameliorated chronic intestinal fibrosis in a colitis-associated model. TM5441 attenuated hypertension-associated vascular remodeling and senescence in an L-NAME model, extending the anti-aging rationale beyond fibrinolysis into vascular biology. These preclinical findings collectively indicate that PAI-1 inhibition restores matrix turnover balance, suppresses pathological stromal activation, and modulates senescence-associated signaling across tissue compartments.

TM5614 was selected from an in silico screening campaign of approximately two million virtual compounds and iterative synthesis and optimization of more than 1,400 derivatives based on the crystal structure of human PAI-1. It is orally bioavailable and has progressed through formulation, toxicology, and into human clinical evaluation — a progression rare for an academically derived compound. Clinical programs have tested TM5614 in chronic myeloid leukemia, immune-checkpoint-refractory malignant melanoma, non-small-cell lung cancer, and COVID-19-associated pneumonia. The review frames combination with immune checkpoint blockade (e.g., anti-PD-1/PD-L1) as a particularly promising strategy, given the mechanistic overlap between PAI-1-driven stromal immunosuppression and tumor immune evasion. Key caveats include the fact that clinical efficacy data remain preliminary, most preclinical effect sizes were generated with earlier-generation inhibitors rather than TM5614 itself, and bleeding risk from fibrinolytic enhancement requires careful monitoring in future trials.